These cases are likely to be more rarely observed in daily practice, albeit, extrapolating from our study and from breast cancer epidemiology, they may represent a small but clinically relevant breast cancer population not benefitting from anti-HER2 treatments. Here, ERBB2 is linked to breast cancer.